trending Market Intelligence /marketintelligence/en/news-insights/trending/qxpmsx_vtvviy7oex6v5jq2 content esgSubNav
In This List

Teva returns rights to Active Biotech's brain disease drug after trial failures

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Teva returns rights to Active Biotech's brain disease drug after trial failures

Teva Pharmaceutical Industries Ltd has returned the global rights to Active Biotech AB's medicine for neurodegenerative diseases after ceasing clinical development of the drug.

Israel's Teva secured the rights to laquinimod in 2014 for an upfront payment of $5 million, plus another $92 million if the medicine met certain milestones. Laquinimod, however, failed in trials for treating Huntington's disease and multiple sclerosis. But the drug did succeed in reducing brain atrophy, a common feature of many diseases that affect the brain. Brain atrophy is a loss of neurons in the brain.

Active Biotech CEO Helén Tuvesson said the company "will assess all opportunities for a continuation of the development of laquinimod."

As of 1:12 p.m. Central European Summer Time, Sweden-based Active Biotech's stock was down 5.95% on the Nasdaq OMX Nordic Exchange.